List of Excipients in Branded Drug MIGLUSTAT

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
CoTherix Inc	MIGLUSTAT	miglustat	10148-201	FERROSOFERRIC OXIDE
CoTherix Inc	MIGLUSTAT	miglustat	10148-201	GELATIN
CoTherix Inc	MIGLUSTAT	miglustat	10148-201	MAGNESIUM STEARATE
CoTherix Inc	MIGLUSTAT	miglustat	10148-201	POVIDONE K30

Generic Drugs Containing MIGLUSTAT

Company	Ingredient	NDC	Excipient
Edenbridge Pharmaceuticals LLC	miglustat	42799-708	FERROSOFERRIC OXIDE
Edenbridge Pharmaceuticals LLC	miglustat	42799-708	GELATIN
Edenbridge Pharmaceuticals LLC	miglustat	42799-708	MAGNESIUM STEARATE
Edenbridge Pharmaceuticals LLC	miglustat	42799-708	POVIDONE

What are the Most Frequently-Used Excipients in MIGLUSTAT?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 1
1	FD&C BLUE NO. 2

Miglustat Excipient Strategy and Commercial Opportunities

Last updated: October 21, 2026

Miglustat is an oral iminosugar with established use in Gaucher disease type 1 and Niemann-Pick disease type C. Its commercial opportunity is no longer centered on core-molecule exclusivity. The strongest opportunities are differentiated oral dosage forms, lactose-free products, pediatric administration, GI-tolerability improvements, regional generic supply, and excipient systems that support stable, low-cost capsule or multiparticulate manufacturing.

The reference product, Zavesca, is a 100 mg immediate-release hard capsule. Miglustat has high aqueous solubility but is associated with dose-related gastrointestinal adverse effects, including diarrhea, flatulence, and abdominal discomfort. Those characteristics create a practical formulation target: improve administration and tolerability without compromising rapid absorption or increasing manufacturing complexity.

What is miglustat and how is it commercialized?

Miglustat is N-butyl-deoxynojirimycin, an orally active iminosugar. It inhibits intestinal disaccharidases and reduces glycosphingolipid synthesis through glucosylceramide synthase inhibition. Its approved uses vary by jurisdiction.

Attribute	Miglustat
Active ingredient	Miglustat, also called N-butyl-deoxynojirimycin
Primary dosage form	100 mg hard capsule
Reference brand in the United States	Zavesca
Original sponsor	Actelion Pharmaceuticals
Current corporate ownership	Actelion assets acquired by Johnson & Johnson
U.S. NDA	021348
U.S. Gaucher approval	2003
U.S. NPC approval	2008
Main indications	Gaucher disease type 1 in selected adults; Niemann-Pick disease type C
Administration	Oral, usually three times daily for approved adult regimens
Major tolerability issue	Gastrointestinal effects caused by intestinal carbohydrate-digestion inhibition
Regulatory category	Small-molecule drug, not a biologic

The European Medicines Agency approved Zavesca for adult patients with mild-to-moderate type 1 Gaucher disease when enzyme replacement therapy is unsuitable and for progressive neurological manifestations in adult and pediatric patients with Niemann-Pick disease type C.[1]

Miglustat is also sold through generic and regional brands, including products marketed as Miglustat and Yargesa in selected countries. Market access differs by jurisdiction because orphan-drug rules, national reimbursement, procurement systems, and local registrations have greater commercial importance than U.S. brand competition alone.

What excipients are used in commercial miglustat capsules?

The U.S. Zavesca label identifies a hard gelatin capsule containing inactive ingredients that include starch, povidone, magnesium stearate, gelatin, and color components.[2] Product composition can differ by market and manufacturer. The excipient strategy is therefore not limited to copying the reference capsule.

A conventional miglustat capsule has a relatively simple formulation profile:

Formulation element	Commercial function	Strategic assessment
Starch	Diluent, disintegrant, processing aid	Low-cost and familiar; may support rapid capsule opening
Povidone	Binder and powder-processing aid	Useful for granulation and content uniformity
Magnesium stearate	Lubricant	Effective at low levels but excessive use can slow wetting or dissolution
Gelatin shell	Capsule structure	Familiar but unsuitable for some vegetarian, religious, and animal-origin policies
Titanium dioxide or other colorants	Appearance and identification	May be avoidable in transparent or HPMC systems
Lactose, where used by a regional product	Diluent	Commercial limitation for lactose-intolerant or lactose-avoidant patients

The formulation is technically accessible. A generic manufacturer does not need a complex enabling platform to produce an immediate-release capsule. The commercial question is whether a new product can offer a meaningful benefit in a rare-disease market where volumes are limited and prescribers may prioritize uninterrupted supply over minor dosage-form changes.

Which excipient problems create the best commercial opportunities?

The highest-value opportunity is GI tolerability. Miglustat-associated diarrhea and flatulence are pharmacologically linked to intestinal enzyme inhibition, so excipients cannot eliminate the mechanism. They can, however, support slower local exposure, improved administration, better dose flexibility, or a formulation that reduces peak intestinal concentrations.

1. Lactose-free and low-excipient capsules

A lactose-free product can address patients with lactose intolerance, dietary restrictions, or sensitivity to unnecessary formulation components. The opportunity is strongest in countries where the reference or local generic product uses lactose and where pharmacy substitution is common.

Potential platforms include:

• Microcrystalline cellulose with low-substituted hydroxypropyl cellulose
• Pregelatinized starch
• Mannitol or isomalt for higher-value products
• HPMC capsules instead of gelatin
• Silicon dioxide for flow improvement
• Low-level sodium stearyl fumarate as an alternative lubricant

The commercial advantage is straightforward labeling and broader patient acceptability. The weakness is limited clinical differentiation unless the product is linked to a documented excipient-related need.

2. Vegetarian and vegan capsule systems

HPMC capsules can replace gelatin. This supports procurement in markets and institutions that restrict animal-derived materials. HPMC shells also provide an option for patients who avoid bovine or porcine gelatin.

The formulation challenge is moisture management. Miglustat capsules must maintain content uniformity and dissolution over the proposed shelf life. HPMC capsules generally have different moisture behavior from gelatin shells, so packaging selection becomes important. High-barrier blister packaging may be preferable to bottles in humid climates.

3. Pediatric multiparticulates

Niemann-Pick disease type C can affect children, while the commercial capsule is designed around adult-sized administration. Pediatric patients may have difficulty swallowing 100 mg capsules, particularly when treatment requires repeated daily dosing.

A pediatric product could use:

• Taste-masked mini-tablets
• Multiparticulate pellets in a capsule
• Sachets containing dispersible granules
• Oral powder for suspension
• A liquid suspension with a calibrated dosing device
• Sprinkle capsules that can be opened and mixed with soft food

The main technical risks are dose uniformity, taste, sedimentation, preservative compatibility, and stability after reconstitution. A dry multiparticulate product avoids some of the stability risks associated with aqueous liquids and can support weight-based dosing more effectively than a fixed-dose capsule.

4. Modified-release systems

Modified release is a potential but higher-risk strategy. The objective would be to reduce local intestinal concentration peaks or simplify dosing. However, miglustat acts partly within the gastrointestinal tract, and delayed or extended release could reduce the desired pharmacodynamic effect or alter tolerability unpredictably.

Potential systems include:

• Hydrophilic matrix tablets
• Gastroretentive systems
• Enteric-coated pellets
• Pulsatile release
• Polymer-coated multiparticulates

A modified-release product would require clinical bridging rather than relying only on in vitro dissolution. For an orphan indication with small patient numbers, the development cost may exceed the commercial return unless the product achieves a major dosing or tolerability improvement.

How can excipients address miglustat gastrointestinal intolerance?

Miglustat diarrhea is commonly managed clinically through dietary counseling, dose adjustment, and antidiarrheal treatment. An excipient system should therefore be positioned as a tolerability-support strategy, not as a claim that the drug’s pharmacology has been neutralized.

Three approaches have commercial relevance.

Immediate-release optimization

A low-viscosity, rapidly wetting capsule can reduce variability in disintegration and prevent incomplete dosing. This is the lowest-risk path for a generic product. The goal is robust dissolution across physiological pH conditions rather than delayed release.

Useful development controls include:

• Particle-size distribution of miglustat
• Blend uniformity at the target 100 mg strength
• Lubricant concentration and mixing time
• Capsule-shell moisture
• Dissolution in multiple media
• Stability under high humidity
• Comparative impurity profiling

Moderate-release multiparticulates

Multiparticulates can distribute the dose through the GI tract. A polymer-coated pellet may reduce localized exposure while preserving overall release. This approach requires pharmacokinetic and clinical assessment because a product that changes local intestinal exposure may also change efficacy.

Patient-controlled dosing

A capsule or sachet that can be opened and divided into validated portions may have greater practical value than a complicated controlled-release system. This is especially relevant for pediatric patients and for patients who require temporary dose reduction during treatment initiation.

The formulation must prevent segregation. A powder that appears easy to divide may not provide accurate dosing unless it is packaged in unit-dose sachets or supplied with a validated dispenser.

What formulations are protected by miglustat patents?

Core miglustat composition-of-matter protection is not the principal barrier to market entry. The original active-ingredient and therapeutic-use patent position is mature, and the U.S. orphan exclusivity periods for the original indications have expired.

The remaining IP opportunities are more likely to involve:

• Pediatric dosage forms
• Taste-masked formulations
• Modified-release delivery
• Stable liquid suspensions
• Specific particle-size distributions
• Combination treatment
• Manufacturing processes
• New therapeutic uses
• Dosing regimens linked to a defined patient population

A formulation patent would need a credible technical effect. A patent that merely replaces starch with microcrystalline cellulose, or gelatin with HPMC, may face obviousness and lack-of-inventive-step challenges unless supported by comparative data.

For a new excipient platform, the strongest patent package would connect:

1. A defined composition range.
2. A measurable manufacturing or stability benefit.
3. A dissolution or bioavailability profile.
4. A clinically relevant tolerability or adherence outcome.
5. A specific patient population, such as pediatric NPC patients.

What is the Orange Book status of miglustat?

The U.S. reference product is Zavesca under NDA 021348. FDA approval records identify the original approval and later labeling history.[3] The U.S. orphan exclusivity associated with the original indications has expired. Public Orange Book information does not indicate that a current, unexpired listed patent is the primary barrier to an ANDA for a conventional miglustat capsule.[4]

That position lowers the legal risk for a standard immediate-release generic. It does not remove regulatory work. An ANDA sponsor still must demonstrate pharmaceutical equivalence and bioequivalence, satisfy chemistry, manufacturing, and controls requirements, and address any applicable labeling or facility obligations.

Paragraph IV challenges and generic entry

A Paragraph IV certification would be relevant only if an unexpired patent were listed for the reference product. For a conventional miglustat capsule, the commercial constraint is more likely to be market size, supply reliability, orphan-disease distribution, and reimbursement than a patent injunction.

A new formulation that relies on its own patents could create a different litigation profile. A branded reformulation sponsor may sue an ANDA applicant based on formulation or method-of-use patents even when the original compound patents have expired. Conversely, a generic sponsor can design around such claims by using a noninfringing excipient system and a narrow label.

When does miglustat lose exclusivity?

Miglustat has already lost the principal U.S. exclusivity associated with its original indications.

Exclusivity or protection	Approximate status
U.S. Gaucher disease orphan exclusivity	Expired, based on 2003 approval
U.S. NPC orphan exclusivity	Expired, based on 2008 approval
Conventional capsule compound protection	Mature and not the principal current barrier
U.S. listed-patent barrier for standard capsule	No current listed patent barrier identified in public Orange Book records
Regulatory data package	Originator data exclusivity is no longer the key market barrier
Formulation-specific protection	Product-dependent; potentially available for new inventions

The European Union has separate rules for orphan-market exclusivity and pediatric incentives. Because those periods are jurisdiction-specific, a commercial launch must be assessed country by country rather than by applying the U.S. timeline globally.[1]

How strong is the patent estate for an excipient-based miglustat product?

The patent estate for a new excipient product can be moderate if it covers a clinically meaningful delivery problem. It is weak if it only claims routine substitution of one conventional excipient for another.

Stronger claim themes

• A stable, low-dose oral suspension with defined particle-size and sedimentation limits
• A pediatric multiparticulate product that delivers accurate weight-based doses
• A taste-masking system that preserves rapid release
• A formulation that maintains dissolution after storage at high humidity
• A delivery system supported by reduced treatment discontinuation or improved adherence
• A manufacturing process that improves content uniformity at commercial scale

Weaker claim themes

• Generic HPMC substitution without a demonstrated benefit
• Broad claims to any pharmaceutically acceptable excipient
• Routine use of mannitol, starch, or microcrystalline cellulose
• A broad “improved tolerability” claim without controlled clinical evidence
• A formulation that requires no special manufacturing step and has no unexpected result

The best filing strategy is layered. A composition claim should be supported by process claims, dissolution specifications, packaging claims, and method-of-use claims. International filings should prioritize jurisdictions with meaningful orphan-disease demand and local generic competition, including the United States, European Union, Japan, Canada, Australia, Brazil, and selected Middle Eastern and Asian markets.

Which companies are challenging or competing with miglustat?

Competition is fragmented. Zavesca remains the reference brand, while generic manufacturers and regional licensees supply markets outside the originator’s strongest commercial territories.

The competitor groups are:

• Generic capsule manufacturers
• Regional pharmaceutical companies with orphan-drug portfolios
• Specialty distributors
• Compounding pharmacies in jurisdictions where permitted
• Developers of alternative therapies for Gaucher disease
• Companies supplying substrate-reduction or enzyme-replacement treatments

Miglustat also competes clinically with enzyme replacement therapy and other substrate-reduction therapies. In Gaucher disease, eliglustat and enzyme replacement therapies can limit the addressable patient population for miglustat. In NPC, the competitive set is narrower, and the need for chronic oral treatment creates greater value for pediatric delivery improvements.

How does miglustat compare with eliglustat and enzyme replacement therapy?

Factor	Miglustat	Eliglustat	Enzyme replacement therapy
Modality	Small-molecule oral drug	Small-molecule oral drug	Intravenous biologic therapy
Administration	Oral, repeated daily dosing	Oral, genotype and metabolism considerations	Infusion-based
Formulation opportunity	High for pediatric and GI-tolerability products	Moderate, with oral dosage-form competition	Low for excipient innovation; infusion formulation is specialized
Main commercial advantage	Oral option and NPC relevance	Stronger Gaucher positioning in suitable patients	Established efficacy and broad Gaucher use
Main limitation	GI tolerability and repeated dosing	CYP2D6 status and drug interactions	Infusion burden and cost
Excipient commercial whitespace	Pediatric suspension, multiparticulates, lactose-free capsule	Adherence and formulation convenience	Limited outside infusion-device and stability systems

Miglustat’s strongest commercial niche is not a broad Gaucher replacement market. It is a targeted orphan product with a differentiated opportunity in NPC, pediatric administration, and access markets.

What FDA regulatory pathway applies to a new miglustat excipient product?

A conventional generic 100 mg capsule would generally pursue an ANDA if it is pharmaceutically equivalent to the reference product and can meet FDA bioequivalence requirements.[5] A new dosage form, liquid, modified-release product, or clinically differentiated formulation may require a 505(b)(2) application.

Product concept	Likely U.S. pathway
Same-strength immediate-release capsule	ANDA
HPMC capsule with same dosage form and equivalent performance	Potentially ANDA, subject to FDA determination
Oral suspension	Likely 505(b)(2), unless a suitable generic pathway exists
Modified-release product	Likely 505(b)(2)
Pediatric sprinkle formulation	Often 505(b)(2), depending on equivalence and labeling
New indication or major clinical claim	505(b)(2) or full NDA, depending on reliance and evidence

A 505(b)(2) strategy can support stronger product differentiation but requires more clinical and regulatory investment. It is more defensible when the formulation solves a recognized administration problem.

What manufacturing and IP barriers exist?

Manufacturing barriers are manageable for standard capsules but increase sharply for pediatric and modified-release systems.

Key barriers include:

• Reliable API particle-size control
• Prevention of blend segregation
• Accurate low-dose subdivision
• Moisture control in gelatin or HPMC shells
• Taste masking without delayed release
• Uniform coating of multiparticulates
• Suspension redispersibility
• Preservative and microbial-control strategy for liquids
• Packaging that protects against humidity
• Commercial-scale validation for orphan-market batch sizes

For a conventional capsule, the principal cost risk is underutilization of manufacturing capacity. For a pediatric or modified-release product, the principal risk is development complexity and the need for clinical bridging.

What licensing deals could support miglustat commercialization?

A practical licensing structure would pair an API or finished-dose manufacturer with a specialty company that controls rare-disease distribution. Potential deal assets include:

• Regional rights to a generic capsule
• A pediatric sprinkle or suspension platform
• HPMC capsule technology
• Taste-masking technology
• High-barrier packaging
• Orphan-drug market access and reimbursement capability
• Local pharmacovigilance and named-patient supply

A specialty company may value supply continuity more than a marginal formulation improvement. A manufacturer with validated low-volume production can therefore create licensing value even without a new patent, provided it can offer reliable API sourcing, regulatory documentation, and multi-country release capability.

What is the revenue exposure and market opportunity?

Miglustat is a niche product. Revenue potential depends on patient prevalence, reimbursement, treatment duration, net price, and competition from enzyme replacement and other substrate-reduction therapies.

The most attractive commercial segments are:

1. Pediatric NPC formulations.
2. Generic supply in countries with limited access to Zavesca.
3. Lactose-free and vegetarian capsules.
4. Unit-dose products supporting dose titration.
5. Regional products with reliable orphan-drug distribution.
6. Formulations that reduce swallowing burden without requiring a complex controlled-release claim.

A standard generic capsule may produce modest revenue because patient numbers are small and price competition is likely. A differentiated pediatric product can support higher pricing if it reduces administration burden and improves adherence. The commercial case is strongest where the product can obtain regulatory exclusivity, orphan incentives, or reimbursement preference.

Key Takeaways

• Miglustat’s original U.S. orphan exclusivity has expired, and core-molecule protection is not the main barrier to generic entry.
• The reference product is a 100 mg immediate-release hard capsule with a conventional excipient system.
• GI intolerance is the central formulation challenge, but excipients cannot eliminate the underlying pharmacology.
• The strongest opportunities are pediatric multiparticulates, sprinkle products, oral suspensions, HPMC capsules, lactose-free formulations, and improved dose flexibility.
• A standard immediate-release generic is likely to follow an ANDA pathway; novel dosage forms may require 505(b)(2) development.
• Formulation patents need comparative stability, dissolution, manufacturing, or clinical data to withstand obviousness challenges.
• NPC creates a stronger commercial rationale for pediatric delivery systems than adult Gaucher disease.
• Supply reliability, regional registration, specialty distribution, and reimbursement may matter more than compound patent litigation.
• Licensing value is highest when a formulation technology is combined with orphan-market access and validated low-volume manufacturing.

FAQs

Is miglustat available as a generic drug?

Yes. Miglustat generic products are marketed in multiple countries, although availability, registration status, and reimbursement differ by jurisdiction.

Can miglustat be formulated as a liquid for children?

Yes, but a liquid formulation requires control of taste, sedimentation, microbiological quality, preservative compatibility, dose uniformity, and stability after opening. A dry multiparticulate or sachet product may provide a lower-stability-risk alternative.

Does changing gelatin to HPMC create a patentable miglustat product?

Not by itself. HPMC substitution is generally a routine formulation change unless the product demonstrates an unexpected stability, dissolution, manufacturing, or patient-use benefit.

Is a modified-release miglustat product commercially attractive?

It can be attractive if it reduces dosing frequency or improves tolerability, but it carries higher clinical and regulatory risk because miglustat’s intestinal pharmacology may be affected by release location and rate.

What is the most defensible commercial strategy for a new miglustat product?

A pediatric, taste-masked, dose-flexible multiparticulate product with strong stability data and orphan-market distribution is more defensible than an undifferentiated capsule containing routine excipients.

References

1. European Medicines Agency. (n.d.). Zavesca: European public assessment report. https://www.ema.europa.eu/

2. U.S. Food and Drug Administration. (n.d.). Zavesca (miglustat) prescribing information. https://www.accessdata.fda.gov/

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Zavesca NDA 021348. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

5. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Product-specific guidances for generic drug development. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions-generics